Helix Announces Peer-Review Publication of V-DOS47 in Frontiers in Immunology Journal

Helix BioPharma (TSX:HBP) shared the publication of a peer-reviewed V-DOS47 manuscript in “Frontiers in Immunology” journal.

As quoted in the press release:

V-DOS47 is Helix’s second DOS47 development candidate following L-DOS47, which is currently in clinical testing for the treatment of non-small cell lung cancer.

The article, entitled “Development and Characterization of a Camelid Single Domain Antibody-Urease Conjugate That Targets Vascular Endothelial Growth Factor Receptor 2”, describes the design and construction of V-DOS47 for breast cancer and other potential indications. The paper can be accessed online at https://doi.org/10.3389/fimmu.2017.00956.

“We are very pleased to present our V-DOS47 research work through a peer-reviewed forum,” said Heman Chao, Ph.D., Chief Executive & Scientific Officer of Helix. “V-DOS47 research and development activities, coordinated by our Polish subsidiary, Helix Immuno-Oncology S.A., have been progressing well. We continue to work closely with our team in Poland to advance the DOS47 platform.”

Click here to read the full press release.

Get the Latest Biotech Investing Stock Information

Get the latest information about companies associated with Biotech Investing delivered directly to your inbox.


By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time.

Biotech Stocks in 2018

Find out how the market will look this year


Leave a Reply